🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Learn more about our recent partnership with Boehringer Ingelheim (Boehringer Ingelheim) to advance a novel, first-in-class bispecific compound to address autoimmune and inflammatory diseases in this FierceBiotech article here: bit.ly/3EuneLZ

Thanks, Boehringer Ingelheim! We are very happy to partner to advance this innovative candidate molecule forward.

Join us at the Festival of Biologics! Our CMO, Matteo Levisetti, MD will keynote on Antigen-specific T cell Engagement in Oncology, and in a later session, our SVP & Head of Research, Steven Quayle, PhD, will discuss our autoimmune program, CUE-401. Learn more: bit.ly/3I7j212

At Cue Biopharma, we’re committed to supporting our local Boston community, and for the third year in a row, we’re proud to have volunteered at The Greater Boston Food Bank (The Greater Boston Food Bank)! A special shoutout to our team who stepped up to make a difference for families in need.

Our CEO, Dan Passeri, will participate in a #FiresideChat at the Citizens Life Sciences Conference to discuss our Immuno-STAT platform including the CUE-100 series, CUE-401, & CUE-501, recently partnered with Boehringer Ingelheim. Access the webcast here: bit.ly/3EUm4cW

Join Cue Biopharma $CUE for a virtual event on May 15 at 11am ET featuring Drs. DiPaolo and Cope as they discuss Cue's biologics platform and potential to selectively activate disease relevant T cells with reduced risk of adverse events. Register: bit.ly/3GFKRSC

Join us on May 15 for a virtual event with expert #KOLs Richard DiPaolo, PhD, and Andrew Cope, MD, PhD, to discuss the unique potential of our novel biologics platform. See details & register here: bit.ly/4d8ug65

At #ASGCT2025 (ASGCT) next week, Ko-Wei Lu, PhD, of Dana-Farber Cancer Institute, will present preclinical proof-of-concept data showing the potential of our Immuno-STAT biologics to control CAR T cell expansion & persistence in vivo. Learn more: bit.ly/3eiSkX8

On May 14, Jesusa Capera-Aragones, PhD, from University of Oxford, UK will present research on our Immuno-STAT biologics for cancer immunotherapy at the European Association for Cancer Research (EACR) Conference. Learn more about the program here: bit.ly/452ddjR

We look forward to our presentation on May 16 at @PEGSBoston #PEGSummit. Ahmet Vakkasoglu, PhD, Associate Director, Biologics Discovery & Innovation at Cue Biopharma will discuss how our Immuno-STAT platform is empowering novel immunotherapies. For more: bit.ly/4jTZWi9

Today, we announced our first quarter 2025 financial results and updated business highlights. Read our press release to learn more: bit.ly/4j34qSe $CUE

#ICYM our Virtual Investor Event, watch the webcast replay for expert insights and key updates on our #autoimmune & #oncology programs, including CUE-401, and CUE-501, recently partnered with Boehringer Ingelheim. Watch here: bit.ly/3GFKRSC

We’re pleased to announce a poster presentation of the investigator-sponsored Phase 2 neoadjuvant #ClinicalTrial for our lead oncology asset in HPV+ #HeadandNeckCancer at the ASCO 2025 Annual Meeting. Access the abstract here to learn more: bit.ly/3HdhOGg #ASCO2025

In addition to a poster at the ASCO 2025 Annual Meeting, we’re pleased to share an abstract publication of our lead oncology asset in HPV+ #HeadandNeckCancer. Read it here for more on the investigator-sponsored Phase 2 neoadjuvant #ClinicalTrial: bit.ly/3SW3unY #ASCO25

#ICYM the preclinical proof-of-concept data presentation at the ASGCT 28th Annual Meeting, you can access the poster on our website to learn more about the potential of our Immuno-STAT biologics to control CAR T cell expansion & persistence in vivo: bit.ly/4kHsmf4

We’re pleased to welcome Jill Broadfoot, CFO of aTyr Pharma, to our Board of Directors! Jill brings decades of #biotech leadership and strategic expertise that will be key as we advance our #autoimmune and #oncology programs. Read her bio to learn more: bit.ly/3T9RdfR

Breakthroughs in immunology & inflammation have made I&I one of biotech’s fastest-growing fields. Our interim CDO, Daniel Baker, M.D., will join Biotechnology Innovation Organization’s #BIO2025 International Convention for a panel on key aspects driving this growth. For details: bit.ly/3HCboRf

We had a great turnout for our panel on innovations fueling growth in immunology & inflammation at #BIO2025. Our CEO, Dan Passeri, joined industry leaders to explore the science & investment driving I&I’s rapid rise. Thanks to Biotechnology Innovation Organization, our fellow panelists, & all who came by!

We're headed to the Oppenheimer & Co. Inc. Innovators in I&I Summit in New York, where our CEO, Dan Passeri, will discuss our innovative I&I program, CUE-401, during the Rheumatology Panel and engage with investors and fellow industry peers in #immunology & #inflammation. #OPCOImmunology

ICYMI: We’re pleased to announce positive FDA feedback reinforcing plans to advance an IND submission for our lead autoimmune candidate CUE-401, a first-in-class bispecific molecule designed to restore immune tolerance in #AutoimmuneDisease. For details: bit.ly/4nrl5Cz